Evaluation of Safety and Effectiveness of the Essure (Model ESS505) Device to Prevent Pregnancy in Women

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2014 by Bayer
Information provided by (Responsible Party):
ClinicalTrials.gov Identifier:
First received: September 19, 2013
Last updated: September 2, 2014
Last verified: September 2014

The Essure System is indicated for women who desire non-incisional permanent birth control (female sterilization) by occlusion of the fallopian tubes. The objective of the study is to evaluate the safety and effectiveness of the Essure System (Model ESS505) for permanent birth control in preventing pregnancy. The Essure ESS505 System includes a design modification that will be studied to determine if it provides immediate birth control, thereby removing the three months waiting period required for the commercially available Essure System Model 305 to be effective.

Condition Intervention
Device: ESS505 (BAY1454033)

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: A Multi-Center, Multi-National Clinical Study to Evaluate the Safety and Effectiveness of the Essure® (Model ESS505) Device to Prevent Pregnancy in Women Who Are Seeking Permanent Contraception

Resource links provided by NLM:

Further study details as provided by Bayer:

Primary Outcome Measures:
  • Number of confirmed pregnancies at 1 year among subjects told to rely on ESS505 for contraception [ Time Frame: 1 year ] [ Designated as safety issue: No ]
    Evaluated after 6000 women-months of reliance have been accumulated

  • Reliance rate, defined as number of subjects told to rely on ESS505 after the Essure confirmation test divided by the number of subjects who had insert placement attempted [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    Evaluated after 3000 women-months of reliance have been accumulated (expected at the same time most subjects with implants have completed their 3 month follow-up visit)

Secondary Outcome Measures:
  • Number of confirmed pregnancies at 10 years among subjects told to rely on ESS505 for contraception [ Time Frame: 10 years ] [ Designated as safety issue: No ]
  • Safety of the ESS505 placement procedure defined as number of subjects who experience an AE assessed as related to the ESS505 placement procedure divided by the number of subjects in who at least one ESS505 was introduced into the fallopian tube [ Time Frame: On day of placement procedure ] [ Designated as safety issue: Yes ]
  • Safety of subsequent wearing of the insert defined as number of subjects who experience an AE assessed as related to wearing of ESS505 divided by the number of subjects in whom the presence of an AE could be assessed [ Time Frame: Up to 10 years ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 590
Study Start Date: September 2013
Estimated Study Completion Date: September 2024
Estimated Primary Completion Date: August 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ESS505
All subjects that sign the informed consent and meet the eligibility criteria will be scheduled for an implant procedure.
Device: ESS505 (BAY1454033)


Ages Eligible for Study:   21 Years to 44 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Female, 21 to 44 years of age, inclusive
  • Body weight within range of 90-300 lbs (40 - 136 kg)
  • Sexually active (minimum of 4 coital acts per cycle)
  • Willing to accept the risk of pregnancy while relying solely on the inserts for contraception
  • Medical history indicates bilateral viable and patent fallopian tubes
  • Agrees to fulfill local requirements for counseling and consent to contraception and sterilization, including any required waiting periods

Exclusion Criteria:

  • Post-menopausal woman
  • Suspected or confirmed pregnancy
  • Post-partum or pregnancy termination ≤6 weeks of scheduled insert placement
  • Past fallopian tube sterilization procedure and/or total or partial salpingectomies
  • Diagnosis of any of the following: tubal, endometrial, or myometrial pathology (which may prevent fallopian tube ostia access), proximal tubal occlusion in either fallopian tube, unicornuate uterus, active or recent upper or lower pelvic infection, gynecologic malignancy
  • Currently taking corticosteroids
  • Known allergy to all contrast media available for use in hysterosalpingogram
  • Scheduled to undergo concomitant intrauterine procedures at the time of insert placement (intrauterine device removal is not considered a concomitant procedure)
  • Any general health condition or systemic disease that may represent, in the opinion of the physician, a potential increased risk associated with device use or pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01948882

Contact: Bayer Clinical Trials Contact clinical-trials-contact@bayerhealthcare.com
Contact: For trial location information (Phone Menu Options '3' or '4') (+)1-888-84 22937

United States, Colorado
Not yet recruiting
Arvada, Colorado, United States, 80005
Not yet recruiting
Aurora, Colorado, United States, 80010
United States, Florida
Not yet recruiting
Boynton Beach, Florida, United States, 33472-2952
United States, Illinois
Not yet recruiting
Arlington Heights, Illinois, United States, 60004
United States, Indiana
Not yet recruiting
Fort Wayne, Indiana, United States, 46825
Not yet recruiting
Newburgh, Indiana, United States, 47630
United States, Michigan
Not yet recruiting
Saginaw, Michigan, United States, 48604
United States, Minnesota
Not yet recruiting
Rochester, Minnesota, United States, 55905
United States, New York
Not yet recruiting
Bronx, New York, United States, 10467
Not yet recruiting
New York, New York, United States, 10032
United States, North Carolina
Not yet recruiting
Asheville, North Carolina, United States, 28801
United States, Ohio
Not yet recruiting
Cincinnati, Ohio, United States, 45255
United States, Texas
Not yet recruiting
Dallas, Texas, United States, 75208
Houston, Texas, United States, 77074
United States, Virginia
Not yet recruiting
Norfolk, Virginia, United States, 23507
United States, Washington
Not yet recruiting
Spokane, Washington, United States, 99202-1334
Canada, Ontario
Not yet recruiting
Hamilton, Ontario, Canada, L8S 4K1
Canada, Saskatchewan
Not yet recruiting
Regina, Saskatchewan, Canada, S4P 0W5
Not yet recruiting
L'Hospitalet de llobregat, Barcelona, Spain, 08906
Not yet recruiting
Córdoba, Spain, 14004
Sponsors and Collaborators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
No publications provided

Responsible Party: Bayer
ClinicalTrials.gov Identifier: NCT01948882     History of Changes
Other Study ID Numbers: 16973
Study First Received: September 19, 2013
Last Updated: September 2, 2014
Health Authority: Canada: Health Canada
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Netherlands: Dutch Health Care Inspectorate
Spain: Agencia Española de Medicamentos y Productos Sanitarios
United Kingdom: Medicines and Healthcare Products Regulatory Agency
United States: Food and Drug Administration

Keywords provided by Bayer:
Birth control

ClinicalTrials.gov processed this record on September 18, 2014